THEY SUPPORT US
Proprietary SGC off-the-shelf platform recapituling both the space and time heterogeneity of the tumor to generate first-in-class treatments
A team of expert leaders and developpers of immuno oncology therapies backed by €30 million euro in funding
A standardized and patented platform offering a limitless potential to address significant unmet needs by reducing cost and symplifying supplies
leading to
Example of colorectal cancer (CRC): a cold tumor defined by heterogeneity, plasticity and treatment resistances
95% of patients (MSS type) have no other solution than outdated chemotherapies
5-year survival < 12% 2nd leading cause of cancer mortality worldwide
No immune reaction can be initiated toward tumor cells
Inefficiency of classical immunotherapy
From “off-the-shelf” tumor banks to first-in-class immunotherapies
Enriched with the molecular fingerprints of tumor heterogeneity and resistances.
Designed to safely unlock the immune system to fight back
Allogeneic cell lines selected to cover wide patient populations of the targeted indication
Stimulation by standards of care and physical shock to reveal + 200 cancer related proteins (CRP), linked to tumor specificity, plasticity and resistances mechanisms validated by proteogenomic and predictive model
DNFB HAPTEN
DINITROFLUOROBENZENE
CANCER RELATED PROTEINS
> Using standards of care and physical shock
> Precision medicine applied to large patient populations
> Proteogenomic profiling matched with biopsies datasets
> Data science & deep learning prediction tools
> Fonctionnal validation by immunoassays
> GMP ready & specifically replicable to other solid tumors
> Platform & Product worldwide patented
CRC, PDAC, HCC
OVARIAN CANCER
FUTURE DEVELOPMENT
other indications
colorectal cancer
other indications
2nd cause of cancer mortality
colorectal cancer
6th cause of cancer mortality
3rd cause of cancer mortality
Invested since 2020
Clinical candidates advancing toward IND filing by 2027
Clinical sites open in 2025 Phase I/II for colorectal cancer patients in 1L (EU & US expansion planned)
patients treatable per batch thanks to our standardized & scalable platform
Eligible patients by 2029
J.Gardette
Co-founder, president
B. Pinteur
Co-founder & CSO
P. Bravetti
CEO
C. Tortorelli
Sr Lead medical affairs
L. Chalus
Head of CMC Operations
D. Ezzedine
Board Member
2024 AWARD BEST BIOTECH (FR)
2024 HEALTHCARE AWARD (FR)
2024 MOST PROMISING PROJECT AWARD (EU)
ALUMNI 2023 CANCER STREAM (CAN)
AWARD 2022 (USA)
ALUMNI 2022 (USA)
2022 NOMINATION BEST PHARMA STARTUP (USA)
2024 AWARD
BEST BIOTECH (FR)
2024 AWARD BEST BIOTECH (FR)
2024 HEALTHCARE AWARD (FR)
2024 MOST PROMISING PROJECT AWARD (EU)
ALUMNI 2023 CANCER STREAM (CAN)
AWARD 2022 (USA)
ALUMNI 2022 (USA)
2022 NOMINATION BEST PHARMA STARTUP (USA)
2021 MATWIN
BORD AWARD (FR)
Copyright 2022 Brenus Pharma – All rights reserved
Parc Industriel Tech Lavaur La Bechade, 63500 Issoire, France – contact@brenus-pharma.com
Brenus’ manufacturing process overpasses the lack of immunogenicity & educates the immune system with visible and multi-specific targets
Selection criteria of starting material (Allogeneic tumor cell lines)
Brenus’ manufacturing process overpasses the lack of antigenicity & educates the immune system with a broad & higher quality range of tumor antigens